Development of cabozantinib for the treatment of prostate cancer [Corrigendum]

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032185/
http://dx.doi.org/10.2147/CE.S67095
_version_ 1782317604786929664
collection PubMed
description
format Online
Article
Text
id pubmed-4032185
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-40321852014-05-27 Development of cabozantinib for the treatment of prostate cancer [Corrigendum] Core Evid Corrigendum Dove Medical Press 2014-05-16 /pmc/articles/PMC4032185/ http://dx.doi.org/10.2147/CE.S67095 Text en © 2014 Vaishampayan. This work is published by Dove Medical Press Ltd, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Ltd, provided the work is properly attributed.
spellingShingle Corrigendum
Development of cabozantinib for the treatment of prostate cancer [Corrigendum]
title Development of cabozantinib for the treatment of prostate cancer [Corrigendum]
title_full Development of cabozantinib for the treatment of prostate cancer [Corrigendum]
title_fullStr Development of cabozantinib for the treatment of prostate cancer [Corrigendum]
title_full_unstemmed Development of cabozantinib for the treatment of prostate cancer [Corrigendum]
title_short Development of cabozantinib for the treatment of prostate cancer [Corrigendum]
title_sort development of cabozantinib for the treatment of prostate cancer [corrigendum]
topic Corrigendum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032185/
http://dx.doi.org/10.2147/CE.S67095

Ejemplares similares